Welcure Drugs & Pharmaceuticals Valuation
Is 524661 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 524661 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 524661's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 524661's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 524661?
Other financial metrics that can be useful for relative valuation.
What is 524661's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | ₹59.45m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | 133.3x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does 524661's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 2x | ||
531686 MPS Pharmaa | 2.5x | n/a | ₹60.8m |
543444 Fabino Life Sciences | 1.5x | n/a | ₹61.1m |
524768 Emmessar Biotech & Nutrition | 3x | n/a | ₹207.0m |
VIVIMEDLAB Vivimed Labs | 1x | n/a | ₹410.4m |
524661 Welcure Drugs & Pharmaceuticals | 4.3x | n/a | ₹59.5m |
Price-To-Book vs Peers: 524661 is expensive based on its Price-To-Book Ratio (4.3x) compared to the peer average (2.3x).
Price to Earnings Ratio vs Industry
How does 524661's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?
Price-To-Book vs Industry: 524661 is expensive based on its Price-To-Book Ratio (4.3x) compared to the Indian Pharmaceuticals industry average (3.6x).
Price to Book Ratio vs Fair Ratio
What is 524661's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 4.3x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate 524661's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.